Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 443  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission


    Article Cited by others

INVITED REVIEW

Orphan drug: Development trends and strategies

Sharma Aarti, Jacob Abraham, Tandon Manas, Kumar Dushyant

Year : 2010| Volume: 2| Issue : 4 | Page no: 290-299

   This article has been cited by
 
1 Challenges in orphan drug development and regulatory policy in China
Alice Cheng,Zhi Xie
Orphanet Journal of Rare Diseases. 2017; 12(1)
[Pubmed]  [Google Scholar] [DOI]
2 Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model
Matthew I. Bellgard,Kathryn R. Napier,Alan H. Bittles,Jeffrey Szer,Sue Fletcher,Nikolajs Zeps,Adam A. Hunter,Jack Goldblatt
Blood Cells, Molecules, and Diseases. 2017;
[Pubmed]  [Google Scholar] [DOI]
3 Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
Lieven Annemans,Ségolčne Aymé,Yann Le Cam,Karen Facey,Penilla Gunther,Elena Nicod,Michele Reni,Jean-Louis Roux,Michael Schlander,David Taylor,Carlo Tomino,Josep Torrent-Farnell,Sheela Upadhyaya,Adam Hutchings,Lugdivine Le Dez
Orphanet Journal of Rare Diseases. 2017; 12(1)
[Pubmed]  [Google Scholar] [DOI]
4 Accelerated Access to Medicines
Jessica Pace,Narcyz Ghinea,Ian Kerridge,Wendy Lipworth
Therapeutic Innovation & Regulatory Science. 2017; 51(2): 157
[Pubmed]  [Google Scholar] [DOI]
5 Pain in an era of armed conflicts: Prevention and treatment for warfighters and civilian casualties
E. George,I. Elman,L. Becerra,Sheri Berg,D. Borsook
Progress in Neurobiology. 2016;
[Pubmed]  [Google Scholar] [DOI]
6 Static and Dynamic Properties of Fluorinated 4-Aryl-1,5-Benzodiazepinones
Olga Martín,Marta Pérez-Torralba,M. Ángeles García,Rosa M. Claramunt,M. Carmen Torralba,M. Rosario Torres,Ibon Alkorta,José Elguero
ChemistrySelect. 2016; 1(4): 861
[Pubmed]  [Google Scholar] [DOI]
7 A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy
Jiayi Huang,Jian L. Campian,Amit D. Gujar,David D. Tran,A. Craig Lockhart,Todd A. DeWees,Christina I. Tsien,Albert H. Kim
Journal of Neuro-Oncology. 2016;
[Pubmed]  [Google Scholar] [DOI]
8 Factors That Affect the Acquisition of Reward Premiums for Promotion of Innovative Drug Discovery in Japan
Shoyo Shibata,Ryotaro Uemura,Takeshi Suzuki
Therapeutic Innovation & Regulatory Science. 2016; 50(1): 56
[Pubmed]  [Google Scholar] [DOI]
9 Orphan Drugs and Potential Novel Approaches for Therapies of ß-Thalassemia: Current Status and Future Expectations
Alessia Finotti,Monica Borgatti,Nicoletta Bianchi,Cristina Zuccato,Ilaria Lampronti,Roberto Gambari
Expert Opinion on Orphan Drugs. 2016; 4(3): 299
[Pubmed]  [Google Scholar] [DOI]
10 Factors influencing the difference between forecasted and actual drug sales volumes under the price–volume agreement in South Korea
Sun-Young Park,Euna Han,Jini Kim,Eui-Kyung Lee
Health Policy. 2016;
[Pubmed]  [Google Scholar] [DOI]
11 A Single-use Strategy to Enable Manufacturing of Affordable Biologics
Renaud Jacquemart,Melissa Vandersluis,Mochao Zhao,Karan Sukhija,Navneet Sidhu,Jim Stout
Computational and Structural Biotechnology Journal. 2016;
[Pubmed]  [Google Scholar] [DOI]
12 A review of the progress and pitfalls of FDA policy process: Planning a pathway for pharmaceutical interventions for hearing loss development
Tanisha L. Hammill
Hearing Research. 2016;
[Pubmed]  [Google Scholar] [DOI]
13 Effectiveness, safety and costs of orphan drugs: an evidence-based review
Igho J Onakpoya,Elizabeth A Spencer,Matthew J Thompson,Carl J Heneghan
BMJ Open. 2015; 5(6): e007199
[Pubmed]  [Google Scholar] [DOI]
14 Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
Todd Gammie,Christine Y. Lu,Zaheer Ud-Din Babar,Silvio Garattini
PLOS ONE. 2015; 10(10): e0140002
[Pubmed]  [Google Scholar] [DOI]
15 In Vitro Screening for Drug Repositioning
Graeme F. Wilkinson,Kevin Pritchard
Journal of Biomolecular Screening. 2015; 20(2): 167
[Pubmed]  [Google Scholar] [DOI]
16 Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
Pengfei Jiang,Rajesh Mukthavavam,Ying Chao,Ila Bharati,Valentina Fogal,Sandra Pastorino,Xiuli Cong,Natsuko Nomura,Matt Gallagher,Taher Abbasi,Shireen Vali,Sandeep C Pingle,Milan Makale,Santosh Kesari
Journal of Translational Medicine. 2014; 12(1): 13
[Pubmed]  [Google Scholar] [DOI]
17 Estimating the budget impact of orphan drugs in Sweden and France 2013–2020
Adam Hutchings,Carina Schey,Richard Dutton,Felix Achana,Karolina Antonov
Orphanet Journal of Rare Diseases. 2014; 9(1): 22
[Pubmed]  [Google Scholar] [DOI]
18 The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases
Kristina Sachs-Barrable,Jocelyn Conway,Pavel Gershkovich,Fady Ibrahim,Kishor M. Wasan
Drug Development and Industrial Pharmacy. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
19 Orphan drugs: the regulatory environment
Pedro Franco
Drug Discovery Today. 2013; 18(3-4): 163
[Pubmed]  [Google Scholar] [DOI]
20 A novel approach to sterile pharmaceutical freeze-drying
Christopher Lee Albert Cherry,Huw Millward,Rose Cooper,John Landon
Pharmaceutical Development and Technology. 2013; : 1
[Pubmed]  [Google Scholar] [DOI]
21 Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Joachim Y. Doua,Jean-Pierre Van Geertruyden
Tropical Medicine & International Health. 2013; : n/a
[Pubmed]  [Google Scholar] [DOI]
22 When Everyone Is an Orphan: Against Adopting a U.S.-Styled Orphan Drug Policy in Canada
Matthew Herder
Accountability in Research. 2013; 20(4): 227
[Pubmed]  [Google Scholar] [DOI]
23 Benefits of investment into modern medicines in Central–Eastern European countries
András Inotai,Guenka Petrova,Dinko Vitezic,Zoltán Kaló
Expert Review of Pharmacoeconomics & Outcomes Research. 2013; : 1
[Pubmed]  [Google Scholar] [DOI]
24 Financing drug discovery for orphan diseases
David E. Fagnan,Austin A. Gromatzky,Roger M. Stein,Jose-Maria Fernandez,Andrew W. Lo
Drug Discovery Today. 2013;
[Pubmed]  [Google Scholar] [DOI]
25 Lipid Control in the Modern Era
Richard V. Milani,Carl J. Lavie
Journal of the American College of Cardiology. 2013; 62(23): 2185
[Pubmed]  [Google Scholar] [DOI]
26 Optimizing efficacy of mucosal vaccines
Ayman Gebril,Manal Alsaadi,Reinaldo Acevedo,Alexander B Mullen,Valerie A Ferro
Expert Review of Vaccines. 2012; 11(9): 1139
[Pubmed]  [Google Scholar] [DOI]
27 Orphan/rare drug discovery through drug repositioning
Ramaiah Muthyala
Drug Discovery Today: Therapeutic Strategies. 2011; 8(3-4): 71
[Pubmed]  [Google Scholar] [DOI]

 

Read this article